Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Director · CEO, President, Chairman · 10% owner | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,164,600 |
Reported balance
After 2026-06-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 400 · Balance 2,164,600 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,825 |
Reported balance
After 2026-06-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-01 · Sale · Disposed 775 · Balance 2,163,825 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,424 |
Reported balance
After 2026-06-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-06-01 · Sale · Disposed 401 · Balance 2,163,424 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,162,500 |
Reported balance
After 2026-06-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-06-01 · Sale · Disposed 924 · Balance 2,162,500 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Roger E. Susi Revocable Trust | 162,950 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 162,950 |
| Common StockSEC Table I · non-derivative | IndirectBy Matthew Susi 2008 Dynasty Trust | 2,062,500 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,062,500 F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2025 Filed Nov 4, 2025 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 446 | $79.82 | $35,599.72 |
DisclosureSEC source: 0001613801-25-000026 · form4-11042025_041101.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,327,054 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $79.50 to $80.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 13:20 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 58 | $79.12 | $4,588.96 |
DisclosureSEC source: 0001613801-25-000023 · form4-10292025_091001.xml · nonDerivative · entry 3 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,327,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $79.07 to $79.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 13:20 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 700 | $78.33 | $54,831.00 |
DisclosureSEC source: 0001613801-25-000023 · form4-10292025_091001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,327,558 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.00 to $78.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 13:20 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,242 | $77.56 | $329,009.52 |
DisclosureSEC source: 0001613801-25-000023 · form4-10292025_091001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,328,258 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.99 to $77.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,423 | $75.41 | $107,308.43 |
DisclosureSEC source: 0001613801-25-000021 · form4-10222025_041001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,332,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $75.22 to $75.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,577 | $74.58 | $266,772.66 |
DisclosureSEC source: 0001613801-25-000021 · form4-10222025_041001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,333,923 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.17 to $75.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 27 | $74.07 | $1,999.89 |
DisclosureSEC source: 0001613801-25-000019 · form4-10142025_041001.xml · nonDerivative · entry 3 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,337,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $74.05 to $74.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,746 | $73.37 | $128,104.02 |
DisclosureSEC source: 0001613801-25-000019 · form4-10142025_041001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,337,527 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $72.93 to $73.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,227 | $72.16 | $232,860.32 |
DisclosureSEC source: 0001613801-25-000019 · form4-10142025_041001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,339,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.65 to $72.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 200 | $72.27 | $14,454.00 |
DisclosureSEC source: 0001613801-25-000017 · form4-10072025_051001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,342,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,800 | $71.70 | $344,160.00 |
DisclosureSEC source: 0001613801-25-000017 · form4-10072025_051001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,342,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.25 to $72.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 429 | $71.03 | $30,471.87 |
DisclosureSEC source: 0001613801-25-000015 · form4-10022025_051007.xml · nonDerivative · entry 3 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,347,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $70.93 to $71.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,448 | $70.41 | $242,773.68 |
DisclosureSEC source: 0001613801-25-000015 · form4-10022025_051007.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,347,929 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $69.90 to $70.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,123 | $69.20 | $77,711.60 |
DisclosureSEC source: 0001613801-25-000015 · form4-10022025_051007.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,351,377 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.86 to $69.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2025 Filed Sep 24, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $71.26 | $356,290.50 |
DisclosureSEC source: 0001613801-25-000013 · form4-09242025_040901.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,352,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.81 to $71.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 17, 2025 Filed Sep 18, 2025 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,546 | $71.88 | $111,127.72 |
DisclosureSEC source: 0001613801-25-000010 · form4-09182025_040901.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,357,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $71.47 to $72.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 17, 2025 Filed Sep 18, 2025 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,454 | $71.00 | $245,239.53 |
DisclosureSEC source: 0001613801-25-000010 · form4-09182025_040901.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Phillip Susi 2008 Dynasty Trust Disclosed balance after: 2,359,046 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.46 to $71.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 27, 2023 Filed Dec 27, 2023 23:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $46.51 | $232,547.00 |
DisclosureSEC source: 0001415889-23-016965 · form4-12272023_061201.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 162,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.50 to $46.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 23:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $46.00 | $230,000.00 |
DisclosureSEC source: 0001415889-23-016965 · form4-12272023_061201.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 167,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 22:15 UTC | IRADIMED CORP IRMD · Entity 4896 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-016907 · form4-12222023_051202.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Matthew Susi 2008 Dynasty Trust Disclosed balance after: 2,062,500 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $45.14 | $225,696.50 |
DisclosureSEC source: 0001415889-23-016785 · form4-12202023_041201.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 172,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $43.80 to $45.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $44.08 | $220,402.50 |
DisclosureSEC source: 0001415889-23-016785 · form4-12202023_041201.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 177,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.33 to $45.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.82 | $214,113.00 |
DisclosureSEC source: 0001415889-23-016362 · form4-12132023_041205.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 182,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $41.17 to $43.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $41.24 | $206,190.50 |
DisclosureSEC source: 0001415889-23-016362 · form4-12132023_041205.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 187,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.50 to $41.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $41.42 | $207,109.50 |
DisclosureSEC source: 0001415889-23-015924 · form4-12062023_041202.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 192,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.67 to $42.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.11 | $210,568.00 |
DisclosureSEC source: 0001415889-23-015924 · form4-12062023_041202.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 197,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.00 to $42.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 28, 2023 Filed Dec 1, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $40.37 | $201,861.50 |
DisclosureSEC source: 0001415889-23-015687 · form4-12012023_041201.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 202,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.02 to $41.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 27, 2023 Filed Dec 1, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $41.80 | $209,006.00 |
DisclosureSEC source: 0001415889-23-015687 · form4-12012023_041201.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 207,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.25 to $43.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.16 | $210,813.50 |
DisclosureSEC source: 0001415889-23-015410 · form4-11222023_041101.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 212,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $41.77 to $43.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.80 | $213,993.00 |
DisclosureSEC source: 0001415889-23-015410 · form4-11222023_041101.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 217,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.12 to $43.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.91 | $214,547.50 |
DisclosureSEC source: 0001415889-23-015192 · form4-11162023_041108.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 222,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.00 to $43.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $41.06 | $205,313.50 |
DisclosureSEC source: 0001415889-23-015192 · form4-11162023_041108.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 227,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.09 to $41.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 21:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $41.34 | $206,711.00 |
DisclosureSEC source: 0001415889-23-014945 · form4-11092023_041101.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 232,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.73 to $43.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2023 Filed Nov 9, 2023 21:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.91 | $214,535.50 |
DisclosureSEC source: 0001415889-23-014945 · form4-11092023_041101.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 237,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.35 to $44.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $40.40 | $202,016.50 |
DisclosureSEC source: 0001415889-23-014659 · form4-11012023_041101.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 242,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $39.81 to $40.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $39.92 | $199,587.50 |
DisclosureSEC source: 0001415889-23-014659 · form4-11012023_041101.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 247,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.99 to $40.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $39.21 | $196,029.00 |
DisclosureSEC source: 0001415889-23-014568 · form4-10272023_041001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 252,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.83 to $39.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 24, 2023 Filed Oct 27, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $39.04 | $195,187.00 |
DisclosureSEC source: 0001415889-23-014568 · form4-10272023_041001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 257,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.59 to $39.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 18, 2023 Filed Oct 19, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $38.98 | $194,881.50 |
DisclosureSEC source: 0001415889-23-014435 · form4-10192023_041001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 262,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.76 to $39.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $39.35 | $196,756.00 |
DisclosureSEC source: 0001415889-23-014435 · form4-10192023_041001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 267,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.08 to $39.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 11, 2023 Filed Oct 12, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $39.11 | $195,543.00 |
DisclosureSEC source: 0001415889-23-014137 · form4-10122023_041001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 272,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.50 to $40.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $40.48 | $202,396.00 |
DisclosureSEC source: 0001415889-23-014137 · form4-10122023_041001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 277,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.93 to $41.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.70 | $213,497.00 |
DisclosureSEC source: 0001415889-23-014026 · form4-10052023_041001.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 282,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.33 to $43.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.82 | $214,110.00 |
DisclosureSEC source: 0001415889-23-014026 · form4-10052023_041001.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 287,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.23 to $43.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 27, 2023 Filed Sep 28, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,028 | $44.04 | $177,386.68 |
DisclosureSEC source: 0001415889-23-013628 · form4-09282023_040903.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 292,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.90 to $44.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,972 | $42.79 | $255,547.85 |
DisclosureSEC source: 0001415889-23-013628 · form4-09282023_040903.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 296,978 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.30 to $43.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $45.69 | $228,442.50 |
DisclosureSEC source: 0001415889-23-013460 · form4-09202023_040901.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 302,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.47 to $46.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $46.11 | $230,563.50 |
DisclosureSEC source: 0001415889-23-013460 · form4-09202023_040901.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 307,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.43 to $47.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,899 | $43.19 | $298,000.24 |
DisclosureSEC source: 0001415889-23-013230 · form4-09132023_050902.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 312,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $43.00 to $43.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,101 | $45.38 | $140,712.22 |
DisclosureSEC source: 0001415889-23-013230 · form4-09132023_050902.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 319,849 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.72 to $47.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.